The purpose of this study is to measure the safety and decrease in sleepiness in subjects with narcolepsy type 2 (NT2) when taking ALKS 2680 tablets compared to placebo tablets.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
80
Change in Mean Sleep Latency (MSL) on the Maintenance Wakefulness Test (MWT)
Time frame: Baseline to Week 8
Change in Epworth Sleepiness Scale (ESS)
Participants will be asked to complete the ESS, reporting on the level of sleepiness they experienced over the past 7 days.
Time frame: Baseline to week 8
Incidence of adverse events
Time frame: Up to 21 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Alkermes Investigator Site
Little Rock, Arkansas, United States
Alkermes Investigator Site
Los Angeles, California, United States
Alkermes Investigator Site
Redwood City, California, United States
Alkermes Investigator Site
San Francisco, California, United States
Alkermes Investigator Site
Santa Ana, California, United States
Alkermes Investigational Site
Aurora, Colorado, United States
Alkermes Investigator Site
Colorado Springs, Colorado, United States
Alkermes Investigator Site
Brandon, Florida, United States
Alkermes Investigator Site
Miami, Florida, United States
Alkermes Investigator Site
Winter Park, Florida, United States
...and 37 more locations